Abstract |
Apelin, a peptide with several active isoforms ranging from 36 to 12 amino acids and its receptor APJ, a G-protein-coupled receptor, are widely distributed. However, apelin has emerged as an adipokine more than fifteen years ago, integrating the field of inter-organs interactions. The apelin/APJ system plays important roles in several physiological functions both in rodent and humans such as fluid homeostasis, cardiovascular physiology, angiogenesis, energy metabolism. Thus the apelin/APJ system has generated great interest as a potential therapeutic target in different pathologies. The present review will consider the effects of apelin in metabolic diseases such as obesity and diabetes with a focus on diabetic cardiomyopathy among the complications associated with diabetes and APJ agonists or antagonists of interest in these diseases.
|
Authors | I Castan-Laurell, C Dray, P Valet |
Journal | Molecular and cellular endocrinology
(Mol Cell Endocrinol)
Vol. 529
Pg. 111278
(06 01 2021)
ISSN: 1872-8057 [Electronic] Ireland |
PMID | 33838166
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright © 2021 Elsevier B.V. All rights reserved. |
Chemical References |
- APLN protein, human
- APLNR protein, human
- Anti-Obesity Agents
- Apelin
- Apelin Receptors
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
- Metformin
|
Topics |
- Animals
- Anti-Obesity Agents
(therapeutic use)
- Apelin
(genetics, metabolism)
- Apelin Receptors
(genetics, metabolism, therapeutic use)
- Diabetes Mellitus, Type 2
(drug therapy, genetics, metabolism, pathology)
- Diabetic Cardiomyopathies
(drug therapy, genetics, metabolism, pathology)
- Dipeptidyl-Peptidase IV Inhibitors
(therapeutic use)
- Energy Metabolism
(drug effects, genetics)
- Gene Expression Regulation
- Homeostasis
(drug effects, genetics)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Metformin
(therapeutic use)
- Obesity
(drug therapy, genetics, metabolism, pathology)
- Signal Transduction
|